



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

November 12, 2025

Corporate Relationship Department
BSE Limited
Mumbai 400001

The Manager - Listing
National Stock Exchange of India Ltd
Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Press Release under Regulation 30 of the SEBI (LODR) Regulations, 2015

Ref:- Earlier intimations dated July 23, 2025, September 10, 2025 and October 10, 2025

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, November 12th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO")

Adcock Ingram completes delisting from JSE; NATCO Pharma acquires 35.75% stake

NATCO Pharma Limited is pleased to announce the successful completion of the delisting of Adcock Ingram Holdings Limited, one of South Africa's oldest pharmaceutical companies, from the Johannesburg Stock Exchange (JSE) as of November 11, 2025. This landmark event marks the culmination of a strategic acquisition in which NATCO Pharma has acquired 35.75% of Adcock Ingram in a transaction valued at approximately US\$ 226 million (ZAR 4 billion).

With roots tracing back to 1891, Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex. The company has shaped the pharmaceutical landscape in the region for 135 years.

Successful Strategic Acquisition

In July 2025, NATCO Pharma offered ZAR 75 (US\$ 4.36) per share to acquire Adcock Ingram's minority shareholders, a proposal that was approved in October 2025 with thumping support from the shareholders. With the completion of this acquisition of stake, NATCO Pharma attains market presence in South Africa.

Future Direction

The acquisition of stake is expected to create new opportunities for growth and innovation within the region. NATCO Pharma aims to leverage Adcock Ingram's established market position and consumer trust and expand its product offerings further in South Africa and beyond.

Rajeev Nannapaneni, CEO, NATCO Pharma stated, *"This acquisition represents a significant step in our strategic growth plan across the globe. We are committed to preserving the rich legacy of Adcock Ingram while enhancing its capabilities to better serve the healthcare needs of communities across Africa and beyond."*

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of c. US\$ 2 billion. Established in 1981, NATCO Pharma has evolved into a diversified pharmaceutical manufacturer, with a primary focus on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients. NATCO Pharma operates across various geographies (in over 50 countries), including emerging and developed markets, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories. NATCO employs around 5,000 people, with over 520 scientists and researchers at its seven manufacturing and two crop health sciences facilities across India. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).



NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

About Adcock Ingram

Adcock Ingram is a South African pharmaceutical company established in 1891 and ranked 2nd in the private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both the private and public sectors of the market. Its portfolio includes an extensive range of Prescription, Over the counter (OTC), Consumer and Hospital products, manufactured in three facilities in South Africa and two in India. Its extensive portfolio of products includes well-known household brands such as Panado, Allergex, Epi-max, Citro-Soda, and Myprodol. Adcock Ingram has a 10% market share of the private market, is the leader in the OTC pharmaceutical market, and is the largest supplier of hospital and critical care products in South Africa.

For more information please contact

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in